Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population.
about
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infectionThe epidemiological impact of antiretroviral use predicted by mathematical models: a review.Modelling the impact of antiretroviral use in resource-poor settingsCellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in EuropeFactors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP)Resistance of a rodent malaria parasite to a thymidylate synthase inhibitor induces an apoptotic parasite death and imposes a huge cost of fitnessCharacteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, ChinaThe global transmission network of HIV-1Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settingsTransmission fitness of drug-resistant HIV revealed in a surveillance system transmission networkLow proportion of recent human immunodeficiency virus (HIV) infections among newly diagnosed cases of HIV infection as shown by the presence of HIV-specific antibodies of low avidity.Community HIV-1 drug resistance is associated with transmitted drug resistanceHIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.Minority variants of drug-resistant HIV.How HIV treatment could result in effective preventionSexual transmission of single human immunodeficiency virus type 1 virions encoding highly polymorphic multisite cytotoxic T-lymphocyte escape variants.A sensitive assay using a native protein substrate for screening HIV-1 maturation inhibitors targeting the protease cleavage site between the matrix and capsidWhat do mathematical models tell us about the emergence and spread of drug-resistant HIV?Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model.Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.HIV-1 Protease: Structural Perspectives on Drug ResistanceClinical utility of current NNRTIs and perspectives of new agents in this class under development.Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.The HIV Epidemic: High-Income Countries.The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.Transmission of human immunodeficiency virus I drug resistance - a case report. What are the clinical implications?HIV drug-resistant strains as epidemiologic sentinelsAssessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals.Prevalence of and viral outcomes associated with primary HIV-1 drug resistanceDrug resistant HIV: Behaviors and characteristics among Los Angeles men who have sex with men with new HIV diagnosis.Phylogenetic insights into regional HIV transmission.Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection.Active methamphetamine use is associated with transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in individuals with HIV infection of unknown durationClinical significance of human immunodeficiency virus type 1 replication fitness.Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies.Opportunities for sexual transmission of antiretroviral drug resistance among HIV-infected patients in care.Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review.Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe.
P2860
Q24564623-98BC55C1-D684-4548-9233-127A23ADD989Q24814633-7629C42C-7D8C-4FC7-951D-C99AF2A6E957Q25255753-05FEA0EB-E9CC-4415-8FFB-2889FE73D54AQ28474278-51C3EC1F-51BB-4CBF-B1F3-0AD214745416Q28477780-DD6A45BA-5EB3-4765-A231-AAE9BA7B7BB2Q28478613-C2D40768-9338-4567-8D41-F509FB8F2A04Q28539927-DDE2EFE1-420E-493F-9041-12FBC1338451Q30354847-5C7E732F-DD66-401C-877F-ED62074FCB08Q33299456-192A0B47-6782-435E-9DD2-28154F5ED411Q33589187-BBEED9D4-FE49-45CB-A9FC-FC0B16310964Q33592734-2E0E3ABF-46DC-4403-812C-629BBC391A27Q33748960-E8533A42-11F3-44BC-A45B-93D001A81F00Q33982161-A7451308-FB2E-4065-9029-F931E5CE7908Q34047780-8778F3DE-EC73-4908-8D86-B0216EB9EA51Q34090397-38E9525C-E728-49DE-B13C-D66FF2260662Q34123849-064951ED-19C3-4C20-8ACE-CAB4F051DC0AQ34771244-9FFC89FD-0BA5-4E41-9A85-6AC60AE21A13Q34989198-93178435-00BE-4CE4-9CDF-5717F0AD886CQ35107675-3AE271AE-33A0-4B92-84BE-8725F25DB409Q35122466-2DDCE281-A79D-4095-B5C8-68CC96B19BB9Q35259855-CEE617DC-CA7A-4E9F-8C46-34CD57CDBCB7Q35842270-44151EBD-6370-4249-B586-13100A546756Q35842525-A50F39AA-FE3D-4D02-B557-0085341124E8Q35902684-0CAD8335-D9E6-469B-9888-42015BFBB2FCQ35917148-F9DE18E3-3B51-4C79-8030-2CF4ABA2D9B2Q35959266-9C471113-928A-42B8-957A-9EFF45FF20F4Q36026355-8D6EDA65-28B5-438F-950D-7069A980E7C2Q36061979-48C06B6E-0182-40AB-AADF-FD1CBC443516Q36291581-3E6E0A4A-A0DE-46A3-B5C1-ABFA906F572CQ36319734-4A87316E-4514-410D-8DCF-55CA387AED27Q36593951-E6A7275E-BCC8-4826-8C66-2595CBC93A81Q36673315-D397E6EC-5B68-4B97-A736-3F4434C786B9Q36798007-D28166A9-B1A8-447F-93DC-2FDC31D895A0Q36914858-640D55D4-0FBC-4BF9-B26E-52102360807BQ36969857-057F0AFC-7720-455B-938B-B82C3AA9D4D2Q37235740-6B3948DA-B96C-4C84-ACCF-0615E7CCE2E9Q37503352-58E1591F-A9D2-4116-B540-3E221B2D7DA9Q37565063-87E6C19B-8F97-413A-8E16-71332E7C2C57Q38208721-214DF16E-2FE4-4648-9EAA-6A5135199672Q38450409-60D90163-4583-4071-821D-CC8C41F56971
P2860
Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Transmission fitness of drug-r ...... retroviral-treated population.
@en
Transmission fitness of drug-r ...... retroviral-treated population.
@nl
type
label
Transmission fitness of drug-r ...... retroviral-treated population.
@en
Transmission fitness of drug-r ...... retroviral-treated population.
@nl
prefLabel
Transmission fitness of drug-r ...... retroviral-treated population.
@en
Transmission fitness of drug-r ...... retroviral-treated population.
@nl
P2093
P356
P1476
Transmission fitness of drug-r ...... retroviral-treated population.
@en
P2093
Douglas D Richman
Eric S Daar
Keith Dawson
Nicholas S Hellmann
Simon D W Frost
Susan J Little
W Christopher Mathews
P304
P356
10.1086/367989
P407
P577
2003-01-29T00:00:00Z